Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Special Features of Adaptive Immunity

Special Features of Adaptive Immunity

The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development.

Blood advances·2020

Same author

Non-Compartment and compartmental pharmacokinetics, efficacy, and safety of Kedrion FIX concentrate.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2020

Same author

Prophylaxis re-visited: The potential impact of novel factor and non-factor therapies on prophylaxis.

Haemophilia : the official journal of the World Federation of Hemophilia·2018

Same author

Bioengineered molecules for the management of haemophilia: Promise and remaining challenges.

Haemophilia : the official journal of the World Federation of Hemophilia·2018

Same author

Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII.

Haemophilia : the official journal of the World Federation of Hemophilia·2018

Same author

Defining extended half-life rFVIII-A critical review of the evidence.

Haemophilia : the official journal of the World Federation of Hemophilia·2018

Search research articles

Related Experiment Video

Updated: Jul 14, 2026

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

International workshop on immune tolerance induction: consensus recommendations.

D M DiMichele¹, W K Hoots, S W Pipe

¹Department of Pediatrics, Weill Medical College of Cornell University, New York, NY 10021, USA. dmdimich@med.cornell.edu

Haemophilia : the Official Journal of the World Federation of Hemophilia

|August 21, 2007

Summary

Immune tolerance induction (ITI) is a 30-year-old hemophilia treatment, but evidence is limited. This consensus provides recommendations for ITI in hemophilia A and B patients based on literature and expert experience.

More Related Videos

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Related Experiment Videos

Last Updated: Jul 14, 2026

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Generation of Induced Regulatory T Cells from Primary Human Naïve and Memory T Cells

Published on: April 16, 2012

Intralymphatic Immunotherapy and Vaccination in Mice

Intralymphatic Immunotherapy and Vaccination in Mice

Published on: February 2, 2014

Area of Science:

Hematology
Immunology

Background:

Immune tolerance induction (ITI) is a long-standing treatment for hemophilia, aimed at eliminating inhibitors and normalizing factor pharmacokinetics.
Despite its widespread use for three decades, there is a notable lack of robust scientific evidence to guide therapeutic decisions in ITI.
This gap necessitates the development of evidence-based guidelines to support clinicians and hemophilia treatment centers.

Framework:

An international panel of leading hemophilia experts convened to establish consensus recommendations for ITI.
The recommendations encompass patients with severe and mild hemophilia A and hemophilia B.
The framework integrates existing published literature with the collective clinical expertise of the panel.

Implementation:

The consensus process involved a thorough review of available scientific literature.
Clinical experience from a diverse group of hemophilia opinion leaders informed the recommendations.
Recommendations are graded according to the level of supporting evidence.

Implications:

These consensus recommendations offer crucial direction for physicians and hemophilia treatment center staff.
The guidelines aim to standardize and optimize the application of ITI in hemophilia management.
Improved therapeutic decision-making for ITI can lead to better patient outcomes and factor pharmacokinetics.